AFFY  Affymax Inc.

Exchange

NASDAQ

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

8.6M

Current Price

$0.23
+0.01 (+4.55%)

Book Price

$-0.27
Overvalued by 217.38%
Financial Institution

Company Metrics

  • 2.68 P/E
  • 196.38 P/S
  • 1.59 P/B
  • 0.082 EPS
  • 0.00 / N/A % Dividend
  • 583,308.00 Avg. Vol.
  • 37.39M Shares
  • 8.6M Market Cap.

Company Description

Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood ...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Penny Stocks Under Consideration: NOVO RES CORP (NSRPF), Affymax, Inc ...
Techsonian (press release) - Sep 1, 2014
Manhattan, NY- September 01, 2014 - (Techsonian) - NOVO RES CORP (OTCMKTS:NSRPF) engages in the evaluation, acquisition, and exploration of natural resource properties.
Penny Stock's Buzzers - Affymax, Inc. (OTCMKTS:AFFY), ATHABASCA ...
Techsonian (press release) - Sep 1, 2014
Affymax, Inc. (OTCMKTS:AFFY) operates as a biopharmaceutical company in the United States. The company was founded in 2001 and is based in Cupertino, California.
Mid-Day Buzzers – Affymax, Inc. (OTCMKTS:AFFY),Nuvilex Inc (OTCMKTS ...
Techsonian (press release) - Aug 26, 2014
Birmingham, West Midlands - (TechSonian) - 08/26/2014 —Affymax, Inc. (OTCMKTS:AFFY) reported financial results for the second quarter ending June 30, 2014.
Intraday Movers - LOMIKO METALS INC (LMRMF), Discovery Minerals Ltd ...
Techsonian (press release) - Aug 30, 2014
LOMIKO METALS INC (OTCMKTS:LMRMF)advised that it was served with a Notice of Civil Claim by Alpha Capital Anstalt (“Alpha Capital”) filed in the Supreme Court of British Columbia on August 6, 2014.
Lucrative Penny Stocks -Marina Biotech, Inc. (MRNA), ATHABASCA MINERALS ...
Techsonian (press release) - Aug 27, 2014
Marina Biotech, Inc. (OTCMKTS:MRNA)declared that the Company has become current with respect to its obligation to file reports with the Securities and Exchange Commission under Section 13 of the Securities Exchange Act of 1934, having trailed its ...
Stock Runners – Affymax, (AFFY),AMARANTUS BIOSCIENCE, (OTCBB:AMBS ...
Techsonian (press release) - Sep 1, 2014
Houston, TX - Sep 01, 2014 - (Techsonian) - Affymax, (OTCMKTS:AFFY), a biopharmaceutical company, reported that its Board of Directors has approved the liquidation and dissolution of the company, subject to stockholder approval, and plans to distribute ...
Stocks on the Run - Affymax, (OTCMKTS:AFFY),Nano Labs, (OTCMKTS:CTLE ...
Techsonian (press release) - Aug 27, 2014
Birmingham, West Midlands - (TechSonian) - 27 August 2014 - Affymax, (OTCMKTS:AFFY), a biopharmaceutical company, reported that its Board of Directors has approved the liquidation and dissolution of the company, subject to stockholder approval, ...
Penny Stocks on the Run - Tauriga Sciences Inc (TAUG), Neutra Corp (NTRR ...
Techsonian (press release) - Sep 1, 2014
Las Vegas, NV - 1st September, 2014– (TechSonian) –Tauriga Sciences Inc (OTCMKTS:TAUG) proclaimed that it has arrived into an investment banking agreement with Tokyo, Japan based investment banking firm Dragoon Capital, Inc. (“Dragoon”).
Penny Stocks Under Review - Tauriga Sciences Inc (OTCMKTS:TAUG ...
Techsonian (press release) - Sep 1, 2014
Tauriga Sciences Inc (OTCMKTS:TAUG), released that it has entered into an investment banking contract with Tokyo, Japan based investment banking firm Dragoon Capital, Inc. (“Dragoon”). Through this investment banking contract, Dragoon has decided on ...
An Analysis Of Amgen
Seeking Alpha (registration) - Aug 22, 2014
A protein-based competitor to Epogen, Omontys, from Takeda (OTCPK:TKPYY) and Affymax (OTCQB:AFFY), came to market in 2012 and after killing a few people due to severe allergic reactions, was withdrawn last year.